Research programme: pain therapeutics - Cy Biopharma
Latest Information Update: 04 Apr 2024
At a glance
- Originator Cy Biopharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pain
Most Recent Events
- 04 Apr 2024 Early research in Pain in Switzerland (unspecified route) before December 2022 (Cy Biopharma website, April 2024)
- 29 Feb 2024 Cy Biopharma has patent protection for glycosylated psilocin derivatives, worldwide
- 16 Nov 2023 Cy Biopharma has patent protection for glycosylated compositions and methods of use, worldwide